Cardiovascular diseases is one of the major causes of deaths across the globe and the rate of mortality caused by these diseases is expected to reach over 23 million by 2030, according to the World Health Organization. Cardiovascular conditions are largely lifestyle diseases and about 16% of deaths caused by cardiovascular diseases in 2012 were attributable to high blood pressure. Various classes of drugs used for treating cardiac disorders include calcium channel blockers, anti-adrenergic agents, anti-arrhythmic agents, diuretic agents, and angiotensin-converting enzyme (ACE) inhibitors. Anti-adrenergic agents have been recognized as an imperative therapeutic intervention in the treatment of patients with cardiac ailments. Anti-adrenergic agents act by inhibiting the stimulation of the central nervous system and ultimately, by reducing the sympathetic stimulation to the blood vessels and the heart. They primarily block the adrenergic receptors and inhibit their activity. Anti-adrenergic agents reduce the heart rate and relax the blood vessels, which ultimately reduces the blood pressure. This is helpful in treating conditions such as hypertension, angina, and arrhythmia.

Therapeutic innovations, increased disease awareness, and government intervention in curbing the number of deaths caused by cardiovascular diseases have helped in reducing the mortality rate. Statistics published by the American Health Association suggests that the mortality rate per 100,000 reduced from 342.9 in 2000 to 236.6 in 2010 in the U.S. Statins is a major drug class that includes blockbuster drugs such as Lipitor (atorvastatin calcium) and Crestor (rosuvastatin). However, the percentage of prescribing of these drugs in hospital settings is negligible compared to other cardiovascular drugs such as Novarsc (amlodipine), Diovan (valsartan), and VESIcare (solifenacin succinate). The global antiadrenergic agents market for cardiology was valued at US$ 452.6 Mn in 2013 and is expected to expand at a moderate pace during the forecast period.

The global antiadrenergic agents market can be segmented based on type, distribution channel, and region. Based on type, the market can be divided into α blockers and β blockers. The α blockers segment can be further categorized into equilibrium type and non-equilibrium type. The equilibrium type of α blockers further comprise selective and non-selective antiadrenergic drugs. Selective drugs consist of α1 selective drugs and α2 selective drugs. Similarly, β blockers have been divided into non-selective β blockers and selective β blockers. Non-selective β blockers exhibit membrane-stabilizing activity without intrinsic sympathomimetic activity. Some examples of non-selective β Blockers are timolol, propranolol, and sotalol. Examples of selective β blockers include atenolol, metoprolol, acebutolol, esmolol, and butoxamine. Based on distribution channel, the global antiadrenergic agents market can be segmented into hospital pharmacies, clinics, hospitals, retail pharmacies, and online pharmacies.

Based on geography, the global antiadrenergic agents market can be segmented into North America, Europe, Asia Pacific, and Rest of World. North America accounts for a major market share owing to extensive research and development activities, favorable reimbursement policies, and advanced health care infrastructure in the region. Implementation of the Affordable Care Act has imposed significant limitations on hospitals as well as pharmaceutical companies with respect to costing of new drugs. Europe follows North America in the market for antiadrenergic agents, due to comprehensive intellectual property protection and presence of companies and organizations involved in research in the region. However, lack of proper reimbursement and regulatory framework pertaining to new drug development is a key restraint to the market in Europe. Increasing prevalence of cardiovascular diseases in other regions of the world is likely to boost the antiadrenergic agents market in these regions during the forecast period.

Key players operating in the global antiadrenergic agents market are Boehringer Ingelheim GmbH, Pliva, AstraZeneca plc, Pfizer, Inc. and GlaxoSmithKline plc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market      
     

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Anti Adrenergic Agents Market

Pre Book